

Declaration of Interests Register

Committee D

Publication Date: 3 June 2020

Topic: ID1368 Fremanezumab for preventing migraine

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Dr Peter Hall	Committee Member	Indirect non-financial	His institute had received research funding from Novartis on unrelated topics.		22/10/2019		It was agreed that this declaration would not prevent Dr Peter Hall from participating in this section of the meeting.
David Meads	Committee Member	Indirect interests	University of Leeds has received funding from Janssen for research in an unrelated area		10/01/2020		
Brendan Davies	Clinical Expert		Brendan been a UK principal investigator in clinical trials looking at Fremanezumab versus placebo in episodic and chronic migraine in my role as research lead at my hospital trust, University Hospital of North Midlands. My hospital receives commercial research funding and NIHR funding for this work. I have received personal remuneration 2 years ago from TEVA for		06/02/2020		It was agreed that this declaration would not prevent Brendan Davies from participating in this section of the meeting

			information about migraine in the UK.				
--	--	--	--	--	--	--	--